This article presents background information and highlights key findings from a managed care perspective related to enlarged prostate (EP) in Medicare-eligible patients. This article does not provide ...

Prostate cancer remains a significant public health problem. The current approach with prostate-specific antigen (PSA)-based screening has questionable effects on prostate cancer–specific mortality ...

: To evaluate the likelihood of alphaadrenergic antagonist (alpha-blocker) discontinuation in combination with dutasteride or finasteride among patients aged =65 years with enlarged prostate. Methods ...

Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man’s risk of being diagnosed with prostate cancer from around 5–9% to around 4-6% during up to 7 years of ...

SAN FRANCISCO—Prostate biopsies performed after treatment with 5-alpha reductase inhibitors increase the rate of prostate cancer detection, researchers reported at the American Urological Association ...

It is important for urologists and primary care physicians to be aware of the potential link between BPH medications and heart failure risk, according to investigators. Heart failure risk is increased ...

Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no ...

Men who take 5-alpha-reductase inhibitors while on active surveillance for prostate cancer are less likely to experience cancer progression, according to a new study Use of 5-alpha-reductase ...

Long-term use of 5-alpha reductase inhibitors (5-ARIs), used off-label for androgenetic or frontal fibrosing alopecia (FFA) in women, was not associated with an increased risk for osteoporosis or ...

Show More From the Division of Urology, Washington University School of Medicine, St. Louis, MO. Prostate cancer remains a significant public health problem. The current approach with ...